一、审议通过《关于<2023 年半年度报告>及其摘要的议案》 证券代码：300194 证券简称：福安药业 公告编号：2023-051 福安药业（集团）股份有限公司 第五届董事会第十二次会议决议公告 （现场表决和通讯表决相结合方式） 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称 "公司"）第五届董事会第十二 次会议于 2023 年 8 月 29 日在公司会议室召开。应到董事 9 名，实到董事 9 名。 本次会议采用现场表决和通讯表决结合方式召开，其中现场参加会议董事 4 名， 通讯表决方式参加会议董事 5 名。会议通知已于 2023 年 8 月 19 日以电话、传 真、邮件等方式发出。本次会议的召集、召开与表决程序符合《公司法》、公司 章程的规定。 本次会议由董事长汪天祥先生主持，公司监事和高级管理人员列席了会议。 经与会董事认真审议，本次会议审议通过了相关议案，并作出如下决议： 公司《2023 年半年度报告》及其摘要的编制程序符合 法律、行政法规和中 国证监会的规定，报告内容真实、准确、完整地反映了公司的实际经营情 ...

经审核，监事会认为：公司董事会编制和审核《2023 年半年度报告》及其 摘要的程序符合法律、行政法规、中国证监会的规定，报告内容真实、准确、完 整地反映了公司 2023 年半年度经营的实际情况，不存在任何虚假记载、误导性 陈述或者重大遗漏。 《2023 年半年度报告》及其摘要于同日发布于中国证监会指定的创业板上 市公司信息披露网站巨潮资讯网。 表决结果：3 票同意，0 票反对，0 票弃权，本议案获得通过。 证券代码：300194 证券简称：福安药业 公告编号：2023-052 福安药业（集团）股份有限公司 第五届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称 "公司"）第五届监事会第十 一次会议于 2023 年 8 月 29 日在公司会议室召开。应到监事 3 名，实到监事 3 名。会议通知已于 2023 年 8 月 19 日以电话、传真、邮件等方式发出。本次会 议的召集、召开与表决程序符合《公司法》、公司章程的规定。 本次会议由监事会主席杨勇先生主持，公司全体监事出席了会议。经与会监 事认 ...

非经营性资金占用 资金占用方 名称 占用方与上 市公司的关 联关系 上市公司 核算的会 计科目 2023 年期初 占用资金 余额 2023 年 1-6 月 占用累计发生 金额（不含利 息） 2023 年 1-6 月 占用资金的利 息（如有） 2023 年 1-6 月偿还累计 发生金额 2023 年期 末占用资金 余额 占用形成 原因 占用性质 控股股东、实际控制 人及其附属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 前控股股东、实际控 制人及其附属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 其他关联方及其附 属企业 无 不适用 不适用 不适用 不适用 小 计 —— —— —— —— —— 总 计 —— —— —— —— —— 其他关联资金往来 资金往来方 名称 往来方与上 市公司的关 联关系 上市公司 核算的会 计科目 2023 年 期初往来 资金余额 2023 年 1-6 月 往来累计发生 金额（不含利 息） 2023 年 1-6 月 往来资金的利 息（如有） 2023 年 1-6 月 偿还累计 发生金额 2023 年 期末往来 资金余 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 691,025,769.13, representing a year-over-year increase of 25.03% compared to CNY 552,693,027.82 in Q1 2022[5] - Net profit attributable to shareholders for Q1 2023 was CNY 86,023,255.31, a significant increase of 130.86% from CNY 37,261,834.25 in the same period last year[5] - The net profit after deducting non-recurring gains and losses was CNY 75,396,700.92, up 141.06% from CNY 31,277,517.05 in Q1 2022[5] - Basic earnings per share for Q1 2023 were CNY 0.07, reflecting a 133.33% increase from CNY 0.03 in Q1 2022[5] - Total operating revenue for Q1 2023 reached ¥691,025,769.13, an increase of 25.1% compared to ¥552,693,027.82 in the same period last year[24] - Net profit for Q1 2023 was ¥88,250,623.91, significantly higher than ¥37,369,678.01 in Q1 2022, marking an increase of 136%[24] - The net profit attributable to the parent company for Q1 2023 was ¥86,023,255.31, a significant increase of 130.7% compared to ¥37,261,834.25 in the same period last year[26] - The total comprehensive income for Q1 2023 reached ¥89,861,967.18, up from ¥35,001,141.95 in Q1 2022, reflecting a growth of 156.5%[26] - The basic and diluted earnings per share for Q1 2023 were both ¥0.07, compared to ¥0.03 in Q1 2022, indicating a 133.3% increase[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY 67,428,674.56, a decline of 215.68% compared to a net inflow of CNY 58,291,240.96 in the previous year[15] - Cash inflows from operating activities totaled ¥630,138,811.39, an increase from ¥581,681,774.88 in the previous year, representing an 8.3% growth[29] - The net cash flow from operating activities was negative at -¥67,428,674.56, contrasting with a positive net cash flow of ¥58,291,240.96 in the same period last year[29] - Cash flow from financing activities for Q1 2023 was CNY 422,211,794.20, a substantial increase of 435.23% compared to a net outflow of CNY 125,945,830.64 in the same period last year[15] - The company raised ¥503,080,000.00 through financing activities in Q1 2023, compared to only ¥88,000,000.00 in the same period last year, indicating a substantial increase of 471.5%[29] - The net cash flow from financing activities was positive at ¥422,211,794.20, a significant turnaround from a negative cash flow of -¥125,945,830.64 in Q1 2022[29] Assets and Liabilities - Total assets at the end of Q1 2023 were CNY 6,295,381,169.09, an increase of 7.10% from CNY 5,877,980,374.42 at the end of the previous year[5] - Current assets totaled ¥2,331,885,668.81, up from ¥1,927,072,477.67, indicating a rise of 21%[22] - The company's total liabilities increased to ¥2,258,053,259.87 from ¥1,931,511,616.76, reflecting a growth of 16.9%[22] - The total equity attributable to shareholders reached ¥4,033,721,243.87, up from ¥3,945,089,460.91, an increase of 2.2%[22] - The total amount of cash and cash equivalents decreased from 1,010,326,594.35 CNY at the beginning of the year to 688,531,150.99 CNY at the end of the period[20] Shareholder Information - The total number of common shareholders at the end of the reporting period is 43,952[17] - The largest shareholder, Wang Tianxiang, holds 24.00% of the shares, totaling 285,499,420 shares[17] - The company has a total of 214,124,565 shares under lock-up for the largest shareholder, Wang Tianxiang, due to executive lock-up restrictions[19] - The second-largest shareholder, Jiang Chen, holds 2.53% of the shares, totaling 30,062,100 shares[17] - The total number of restricted shares decreased from 223,588,823 to 221,835,508 during the reporting period[19] Expenses and Costs - Total operating costs for Q1 2023 were ¥613,468,747.82, up from ¥530,171,239.60, reflecting a rise of 15.7%[24] - The company reported a significant increase in financial expenses, which rose by 103.30% due to higher interest payments on bank loans[13] - Research and development expenses for Q1 2023 were ¥27,929,150.50, slightly higher than ¥26,813,029.82 in the previous year[24] Market and Future Outlook - The increase in revenue was primarily driven by higher sales volumes of certain products and an increased proportion of products won in national procurement, leading to a decrease in sales expenses as a percentage of revenue[9] - The company has no new product or technology developments mentioned in the reports[18] - There are no significant market expansion or acquisition strategies disclosed in the reports[18] - The company has not provided specific future outlook or performance guidance in the available documents[18] - The company reported a significant decrease in contract liabilities from ¥61,840,402.32 to ¥32,691,760.53, a reduction of 47.3%[22] - The company did not report any net profit from subsidiaries prior to consolidation in Q1 2023, consistent with the previous year[26]

证券代码： 300194 证券简称：福安药业 福安药业(集团)股份有限公司投资者关系活动记录表 编号：2023-001 | 投资者关系活 | □特定对象调研 □ 分析师会议 | | --- | --- | | 动类别 | □ 媒体采访 √ 业绩说明会 | | | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时间 | 2023 年 4 月 7 日 (周五) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 1、董秘汤沁 | | 人员姓名 | 2、财务负责人余雪松 | | | 3、董事长汪天祥 | | | 4、独立董事陈耿 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、请问懂事长，股价反应企业现状，长期在 4 元上下意味着 | | | 是否与企业现状匹配。 | ...

Financial Performance - The company's operating revenue for 2022 was ¥2,421,742,292.37, a decrease of 1.28% compared to ¥2,453,144,920.88 in 2021[25]. - The net profit attributable to shareholders for 2022 was ¥204,607,567.44, representing a significant increase of 168.91% from a loss of ¥296,913,080.60 in 2021[25]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥161,266,687.31, up 149.86% from a loss of ¥323,433,987.92 in 2021[25]. - The net cash flow from operating activities increased by 32.03% to ¥339,498,850.22 in 2022, compared to ¥257,128,839.71 in 2021[25]. - The total assets at the end of 2022 were ¥5,877,980,374.42, an increase of 3.01% from ¥5,706,459,375.59 at the end of 2021[25]. - The net assets attributable to shareholders increased by 5.65% to ¥3,945,089,460.91 at the end of 2022, compared to ¥3,734,107,363.48 at the end of 2021[25]. - The company reported a basic earnings per share of ¥0.17 for 2022, compared to a loss of ¥0.25 in 2021, marking a 168.00% improvement[25]. - The weighted average return on equity for 2022 was 5.33%, a recovery from -7.58% in 2021[25]. - The company achieved operating revenue of 2.422 billion yuan in 2022, remaining stable compared to the previous year[60]. - The net profit attributable to shareholders was 205 million yuan, marking a turnaround from a loss, with profit levels slightly increasing compared to the previous year[60]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[20]. - The company is focusing on enhancing its R&D capabilities to adapt to the evolving pharmaceutical landscape and capitalize on opportunities arising from industry consolidation[35][36]. - The company has 58 drug research and development projects currently in the registration process, indicating a strong pipeline for future products[50]. - The company emphasizes a research and development strategy that combines independent innovation with collaborative efforts, ensuring a continuous and forward-looking R&D process[50]. - The company has made significant progress in product research and development, with multiple drugs approved for production, including acetylcysteine inhalation solution and sodium valproate injection[61][62]. - The company is actively pursuing new product registrations, with 12 drugs currently under review, which could significantly impact future sales[54]. - The company is committed to maintaining high standards in drug development and regulatory compliance, which is crucial for sustaining competitive advantage[56]. - The company has established a comprehensive sales system and network, optimizing market promotion strategies to enhance sales capabilities[62]. - The company maintains a strong focus on R&D as a core competitive advantage, with a well-structured and experienced research team[58]. Risk Management - The company emphasizes the importance of risk awareness regarding future plans and performance forecasts, highlighting potential operational risks[6]. - The company has established a comprehensive risk management framework to address various operational challenges[6]. - The company emphasizes strict compliance with safety, environmental, and quality regulations to mitigate operational risks[115]. Corporate Governance - The company has committed to ensuring the accuracy and completeness of its financial reports, with key personnel affirming the integrity of the annual report[5]. - The company maintains a commitment to corporate governance and social responsibility, aligning its operations with industry standards[20]. - The company has a complete and independent financial management system, including separate bank accounts and tax obligations[125]. - The company has a diverse board with members holding various professional backgrounds, enhancing governance[133]. - The company has engaged in providing guarantees for subsidiaries to secure bank credit facilities, indicating a proactive approach to financial management[140]. - The company emphasizes the protection of shareholder rights and adheres to relevant laws and regulations to ensure fair information disclosure[174]. Environmental Compliance - The company has implemented environmental protection measures, including the construction of specialized facilities to reduce pollutant emissions and prevent major environmental accidents[163]. - The company reported a total discharge of COD at 15.0 tons, with ammonia nitrogen at 0.245 tons, indicating compliance with the discharge standards[165]. - The company maintained pH levels between 6 and 9, with ammonia nitrogen ≤ 45 mg/l and chemical oxygen demand ≤ 500 mg/l, adhering to the wastewater discharge standards[166]. - The company has established a comprehensive monitoring system to ensure all discharge parameters remain within the legal limits[166]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[173]. Employee and Management - The total number of employees at the end of the reporting period is 3,229, with 3,179 from major subsidiaries and 50 from the parent company[148]. - The company has a total of 1,340 production personnel, 388 sales personnel, and 996 technical personnel among its workforce[148]. - The company emphasizes talent development through various training programs to enhance employee skills and capabilities[150]. - The management team includes experienced professionals with backgrounds in various pharmaceutical sectors, enhancing the company's operational capabilities[135]. - The company has established a comprehensive salary mechanism that links compensation to performance and responsibilities[149]. Strategic Initiatives - The company is actively pursuing strategic partnerships and potential acquisitions to bolster its market position[20]. - The company anticipates challenges from industry policies and competition, particularly in the areas of drug pricing and market expansion[111]. - The company will strengthen talent recruitment and training to improve the professional and management capabilities of its workforce[110]. - The company will continue to optimize its product structure and increase market maintenance efforts to enhance core competitiveness[112].

证券代码：300194 证券简称：福安药业 公告编号：2023-024 福安药业（集团）股份有限公司 关于举行2022年度网上业绩说明会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 福安药业（集团）股份有限公司（以下简称"公司"）《2022 年年度报告》已 于 2023 年 3 月 31 日公告于中国证监会指定信息披露网站巨潮资讯网。为进一 步解读公司年度报告，帮助广大投资者更深入全面地了解公司经营情况，公司定 于 2023 年 4 月 7 日（星期五）下午 15:00-17:00 在全景网提供的网上平台举行 2022 年度网上业绩说明会。本次说明会将采用网络远程方式举行，投资者可登 陆投资者互动平台"全景·路演天下"（http://rs.p5w.net ）参与本次业绩说明 会。 出席本次年度业绩说明会的人员有：公司董事长兼总经理汪天祥、财务总监 余雪松、董事会秘书汤沁、独立董事陈耿。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业绩说明会 提前向投资者公开征集问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 7 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2015, representing a year-on-year growth of 15%[18]. - The company's operating revenue for 2015 was ¥708,096,042.52, representing a 57.86% increase compared to ¥448,569,652.31 in 2014[24]. - The net profit attributable to shareholders for 2015 was ¥64,899,360.39, up 41.99% from ¥45,707,273.73 in 2014[24]. - The total assets at the end of 2015 amounted to ¥2,479,086,385.20, reflecting a 35.31% growth from ¥1,832,192,083.80 in 2014[24]. - The total profit for 2015 was CNY 76.37 million, representing a 41.44% increase compared to the previous year[40]. - The company's fixed assets increased by 42.03% compared to the beginning of the period, primarily due to an increase in the scope of consolidation[36]. - The company reported a weighted average return on equity of 3.33% for 2015, up from 2.68% in 2014[24]. - The basic earnings per share for 2015 was ¥0.24, a 33.33% increase from ¥0.18 in 2014[24]. - The company reported a net cash flow from operating activities of CNY 161,026,698.03, a significant increase of 614.99% compared to the previous year[70]. Mergers and Acquisitions - The successful acquisition of Tianheng Pharmaceutical contributed to the diversification of the product portfolio and enhanced overall performance, with a positive impact on earnings[9]. - The company completed an asset restructuring with Ningbo Tianheng Pharmaceutical Co., Ltd. in March 2015, enhancing its asset scale and profitability[33]. - The company is actively pursuing external mergers and acquisitions to enhance its market competitiveness and product range[33]. - The company has successfully acquired Tianheng Pharmaceutical, enhancing its product line and risk resistance[40]. - The company is currently undergoing a major asset restructuring with Yantai Zhichu Pharmaceutical, aiming to optimize resource management and market integration[10]. Research and Development - The company is focused on enhancing its product structure through mergers and acquisitions, as well as independent research and development efforts[6]. - The company’s R&D investment increased, with new products like Cefoperazone and Lacosamide Injection receiving registration or clinical approval[42]. - The company is actively expanding its product pipeline with a focus on anti-infective and oncology medications[63][64]. - The company is pursuing regulatory approvals for a total of 46 products, indicating a robust development strategy[64]. - The company is focusing on both generic and new drug development to enhance its market position[63][64]. Operational Risks - The company faces risks related to industry policy adjustments, which may impact drug pricing and procurement models, necessitating proactive management strategies[5]. - There is a risk associated with the delay in obtaining drug registration approvals, which could lead to missed market opportunities and financial losses[8]. - The company acknowledges the risk of goodwill impairment due to previous acquisitions, which could adversely affect financial performance if the acquired entities do not meet expected revenue growth[11]. - The company is cautious about the increasing depreciation from fixed assets due to ongoing construction projects, which may affect profitability[111]. - The company faces risks from policy adjustments in the pharmaceutical industry, which may impact production and operations[110]. Dividend Distribution - The company plans to distribute a cash dividend of 1 RMB per 10 shares to shareholders, based on a total share capital of 281,999,473 shares as of December 31, 2015[11]. - The cash dividend represents 100% of the total distributable profit, reflecting the company's commitment to shareholder returns[116]. - The cash dividend payout ratio for 2015 was 43.45% of the net profit attributable to ordinary shareholders, which was CNY 64,899,360.39[118]. - The company proposed a cash dividend distribution plan of CNY 1 per 10 shares, totaling CNY 28,199,947.30, based on a total share capital of 281,999,473 shares[117]. Market Position and Strategy - The company is transitioning its product structure from a focus on antibiotics to a collaborative development of antibiotics and specialty drugs[32]. - The company is committed to continuous monitoring of market trends and regulatory changes to mitigate operational risks and ensure sustainable growth[5]. - The company plans to enhance its core competitiveness by focusing on product structure optimization, increasing R&D investment, and pursuing mergers and acquisitions[108]. - The company is focusing on optimizing sales, R&D, and production lines to support long-term growth[103]. - The pharmaceutical industry is experiencing structural adjustments due to new medical reform policies, but there are optimistic growth prospects driven by increased health awareness and technological advancements[107]. Financial Management - The company has maintained a stable financial management strategy with no major changes in investment activities[153]. - The total amount of entrusted financial management funds reached CNY 163,875.9 million, with a balance of CNY 126,233.5 million as of the end of the reporting period[156]. - The company engaged in cash asset management, with entrusted financial products totaling 67.5 million yuan and expected returns of 84.38 thousand yuan for one of the products[154]. - The company has no significant related party transactions or debts during the reporting period[146][147][148]. Shareholder Structure - The company’s total share capital increased from 173,420,000 shares in 2013 to 281,999,473 shares in 2015 due to stock dividends and capital reserve transfers[117]. - The company has a total of 11,034 shareholders at the end of the reporting period[182]. - The company’s largest shareholder, Mr. Wang Tianxiang, has pledged 30,930,502 shares[182]. - The total number of shares held by the board of directors and senior management at the end of the reporting period was 146,145,453 shares[191]. - The company has not reported any changes in the shareholding structure of its major shareholders during the reporting period[185]. Governance and Compliance - The company is committed to maintaining a strong governance structure with independent directors overseeing operations[194]. - The company has not faced any penalties from securities regulatory agencies in the past three years, reflecting compliance and governance integrity[199]. - The company has not engaged in any employee stock ownership plans or other incentive measures during the reporting period[142]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders during the reporting period[134].